REMDESIVIR too pricey for Mexico. Looks like we’ll beat

New Post Public Reply Private Reply Replies (0) Message Board
peacekat
847
REMDESIVIR too pricey for Mexico. Looks like we’ll beat them price wise. Hoping for great results S/C.

https://www.google.com.mx/amp/s/www.razon.com...s-experto/

“Despite the fact that remdesivir, a drug recently endorsed in the United States for the treatment of patients with Covid-19, its costs are extremely high, since it is estimated to cost $ 93,500 or 2.29 million pesos, which is why in our country It would be very difficult to have this drug.

Today in Mexico there is none, and the one in stock is being used for clinical trials and the cost is very high, which would be one of the limitations for its application. It is necessary to analyze the viability of bringing it, to know its cost and how much benefit it gives me, since pure medicine costs more than hospitalization, ”Andreu Comas, virologist at the University of San Luis Potosí, explained to La Razón.

In a consultation with the company Medchem Express, which specializes in pharmaceutical costs, one milligram of this drug costs $ 220, but 10 milligrams cost $ 850. In other words, for a treatment of 1,100 milligrams, at $ 85 per milligram, the total cost would be $ 93,500, and at an exchange rate of 24.55 pesos per dollar, the total would be equivalent to two million 295,425 pesos.

For the experts consulted, this high cost of the drug is due to the fact that it is in the testing stage, although according to the Institute for Clinical and Economic Review (ICER), the cost will drop considerably when the drug begins to become popular, up to four One thousand 500 dollars or 110 thousand 475 pesos one thousand Mexican pesos.
Last April 16, the public reason that, according to a statement by the governor of Puebla, Miguel Barbosa, 60 thousand pesos are spent for each day of hospitalization of a person infected with Covid-19; budget that rises to 82 thousand pesos when intensive therapy is required for the infected.

Yesterday, the undersecretary of Prevention and Health Promotion, Hugo López-Gatell, pointed out in a press conference that although the use of this drug was authorized by the Food and Drug Administration (FDA), it does not mean that it can be applied in a widespread, and cautioned that the scientific evidence on its usefulness is inconclusive.
This is not to say that they are approved for general use outside of the emergency condition. The very explicit technical and legal elements are established that it is only in cases of emergency, ”he explained.

The fact: On Friday, the FDA authorized the emergency use of the experimental drug, although this does not amount to its approval. Evidence lowers recovery time by 31%”

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ZKH and Intel Launch Industrial AI Model at the Edge

Updated Category News Views 84

Industrial Revolution at the Edge Forget the horseless carriage; this time, we're talking about AI stepping onto the factory floor in China. ZKH Group Limited has spun a new yarn in MRO with its AI subsidiary, LingLong Intelligence, partnering up with tech giant Intel to launch the LingLong Insight 1.0. The venue was Intel Connection 2026 in Suzhou, China, where this...

Continue Reading
Hudsonville's Leadership Shift Eyes the Future

Updated Category News Views 128

Hudsonville's New Chapter: Enter CJ Ellens When a firm as storied as Hudsonville Ice Cream elects a new captain at the helm, folks sit up and take notice. CJ Ellens, already well-embedded in the fabric of Hudsonville, is set to steer the ship starting January 1, 2027. This isn't just a revolving door of C-suites, but more like a passing of the torch to someone bred in the...

Continue Reading
Endeavor & GoPath's Game-Changing Cancer Test Launch

Updated Category News Views 88

Breaking Ground in Prostate Cancer Testing Just when you thought the medical field couldn't shake things up further, Endeavor Health and GoPath Diagnostics swoop in with a new genetic test for prostate cancer. This ain't just any run-of-the-mill test—it's the first of its kind to hit the clinical scene. The focus here is on sorting out which men with prostate cancer are...

Continue Reading
PRA Group Marks 30 Years with Nasdaq Bell Ringing

Updated Category News Views 78

A Milestone in Times Square Thirty trips around the sun, and here we are: PRA Group, the change-maker in the world of nonperforming loans, is celebrating by ringing the Nasdaq Opening Bell. It's a pretty big to-do in the financial world to get this nod, standing out in New York City's Times Square, no less. This shindig showcased Martin Sjolund, their President and CEO,...

Continue Reading
Latitude Expands Food Allergy Care to Long Island

Updated Category News Views 139

New Clinic Brings Specialized Care to Long Island Listen, when it comes to healthcare, especially something as life-altering as food allergies, you're not just looking for any run-of-the-mill clinic. You're looking for the right place with the right people who get it. And folks in Long Island are getting something worth celebrating—a new clinic from Latitude Food...

Continue Reading
Potomac Edison Targets Virginia Grid Revamp by 2030

Updated Category News Views 82

Strengthening the Backbone of Virginia's Power Supply Ever had your lights flicker on a windy day and wondered if the power grid would hold? Potomac Edison, under the banner of FirstEnergy Corp., is stepping up with a game plan to fortify the electric spine of Virginia and its neighbors. They're diving into a multi-state adventure, rebuilding and erecting 138 kV...

Continue Reading
Bird-X Welcomes Doolittle to Elevate Sales Strategy

Updated Category News Views 62

Change in Flight: Bird-X Eyes Strategic Growth Well, here's one that might spread its wings wide. Emanuel Doolittle has joined Bird-X, Inc. as Director of Sales and Business Development. Now, let's not beat around the bush — Bird-X isn't a name you'd see thrown around daily stock talks, but it's stirring up interest in the pest control sector without question. Why...

Continue Reading
Tripo AI's New Canvas Redefines 3D Workflow Process

Updated Category News Views 51

Rethinking 3D Content Creation Well, well, well, Tripo AI is shaking things up in the 3D world with its new Agentic Canvas. This isn't just another gizmo to throw in the digital drawer; it's a tool looking to flip the whole 3D game on its head. Picture taking complex 3D workflows and molding them like clay into something that’s efficient and scalable. That’s what...

Continue Reading
Tim Brewer Leads AXA XL's Growth in Commercial Bonds

Updated Category News Views 43

AXA XL Welcomes a New Leader You know, insurance isn't exactly what sets hearts racing, but there's something intriguing about the chess game of leadership changes. AXA XL's latest move? They’ve roped in Tim Brewer to helm their Commercial Bonds for the Americas. A hefty role, sure, but one that comes with its fair share of high-stakes pressure. Kind of like betting on...

Continue Reading
DriveNets' Big Role at FYUZ 26: AI Fabrics Spotlighted

Updated Category News Views 105

Networking Titans Gather at FYUZ 26 Alright, folks, mark the first week of November as a field day for telecom and AI networking enthusiasts. DriveNets, a seasoned player in large-scale networking, is joining forces with some of the industry's giants—AT&T, KDDI, and Broadcom—at the Telecom Infra Project's flagship event, FYUZ 26, unfolding at The Westin Seattle. From...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding McDonald's Stock Growth Over Two Decades

Updated Category News Views 191

The Journey of McDonald's Stock Over 20 Years McDonald's (NYSE: MCD) has demonstrated remarkable performance on the stock market, particularly over the last two decades. An average annual return of 11.75% showcases how the brand has consistently outperformed market expectations, yielding a significant edge of 2.82% annually compared to market benchmarks. As of now,...

Continue Reading
IonQ's Major Breakthroughs in Quantum Computing: Stock Insights

Updated Category News Views 124

IonQ's Breakthrough in Quantum Computing IonQ, Inc. (NYSE: IONQ) is making impressive advancements in the field of quantum computing. Recently, the company unveiled a significant breakthrough regarding high-speed mixed-species quantum logic gates. This advancement is pivotal in facilitating scalable and high-fidelity quantum networking and distributed quantum computing....

Continue Reading
iAnthus Capital Holdings: A Closer Look at Q1 Financials

Updated Category News Views 270

Overview of iAnthus Capital Holdings' Q1 2025 Financial Performance iAnthus Capital Holdings, Inc. is making waves within the regulated cannabis industry across the U.S. As they report their financial outcomes for the first quarter of 2025, shareholders are eager to examine how the company has adjusted its strategies in a dynamic market. Key Financial Highlights In Q1 of...

Continue Reading
Soleno Therapeutics Faces Shareholder Legal Scrutiny

Updated Category News Views 6

Legal Storm Brews for Soleno's Execs When you see Kuehn Law stepping into the ring, you know someone’s ruffling feathers. And this time, the target is Soleno Therapeutics (NASDAQ:SLNO), a name that might ring bells for tech folks dabbling in biotech. They’re under the spotlight because a federal securities lawsuit claims a questionable playbook was in the shuffle....

Continue Reading
FlowGuard Gold CPVC Unveils Exciting Sweepstakes for Plumbers

Updated Category News Views 61

Introducing the FlowGuard Gold CPVC Speed Test Challenge FlowGuard Gold CPVC has launched the Speed Test Challenge Sweepstakes, presenting an exciting opportunity for plumbers to showcase their skills. This engaging sweepstake invites participants to watch a comparison video that measures installation speeds of different plumbing materials, particularly PEX versus CPVC,...

Continue Reading